Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adding Bv improved survival for some Hodgkin patients

Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.

Publish date:: September 28, 2018

Key clinical point: Brentuximab vedotin (Bv), given before and after standard chemotherapy, improved survival in untreated Hodgkin lymphoma.

Major finding: Two-year PFS was 84% for patients treated additionally with Bv, compared with 50% historically for standard therapy.

Study details: A prospective phase 2 study involving 48 elderly patients with Hodgkin lymphoma.

Disclosures: Seattle Genetics supported the investigator-initiated trial. Dr. Evens reported consulting or advisory relationships with Seattle Genetics and several other companies.

Read the article.

Citation:

Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.

This Week's Must Reads

HER2-mutant NSCLC Confers High Brain Metastases Risk,

Lower Death Rate in Lung Cancer Patients Who Enrolled in Clinical Trials,

HIV Drug May Enhance Efficacy of Chemoradiation in Locally Advanced Lung Cancer,

Out-of-Pocket Cost of Oral TKIs Linked to Poor Lung Cancer Survival,

MYSTIC Trial Analysis IDs Mutations Prognostic of mNSCLC Outcomes,

Must Reads in Hodgkin Lymphoma

Regimen shows promise as salvage for classical HL,

Adding Bv improved survival for some Hodgkin patients, Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.

Substantial late mortality risk persists after childhood BMT , Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.

PET findings safely drive chemo decisions in Hodgkin lymphoma patients, Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.

Upswing in childhood lymphomas, Siegel DA et al. ASPHO 2018, Abstract 605.